Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA) Treated with Pediatric Argentine BFM-like Protocol: Real-Word Data on Prognostic Factors and Treatment

Blood (2021) 138 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2021-151448

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Argentina: Results Comparing Matched Related, Unrelated or Haploidentical Donors. a Grupo Argentino De Trasplante De Medula Osea (GATMO) Experience

Jose Ignacio Ignacio Trucco, Mariano Berro, MD, Maria Marta Rivas, MD, Pablo Gabriel Longo, MD, Pablo Andres Garcia, MD, Juan Jose Garcia, MD, Ana Basquiera, MD, Gonzalo Ariel Ferini, MD, Sebastian Yantorno, MD, Jorge Milone, MD, Silvina Palmer, MD, German Stemmelin, MD, Alejandro Requejo, MD, Gregorio Jaimovich, MD, Adriana Vitriu, MD, Maria Cecilia Foncuberta, MD, Juliana Martinez Rolon, MD, Gustavo Kusminsky, MD

Blood (2017) 130 (Supplement 1): 5558.

https://doi.org/10.1182/blood.V130.Suppl_1.5558.5558

Published: 2017

Journal Articles

Comparison of Outcomes after Matched Sibling, Unrelated, or Haploidentical Allogeneic Hematopoietic Cell Transplantations (HCT). a Real World Experience of Gatmo (Grupo Argentino de Trasplante de Médula Ósea)

Jose Ignacio Ignacio Trucco, Mariano Berro, MD, Maria Marta Rivas, MD, Pablo Gabriel Longo, MD, Juan Jose Garcia, MD, Pablo Andres Garcia, MD, Ana Basquiera, MD, Gonzalo Ariel Ferini, MD, Sebastian Yantorno, MD, Jorge Milone, MD, Silvina Palmer, MD, German Stemmelin, MD, Alejandro Requejo, MD, Gregorio Jaimovich, MD, Adriana Vitriu, MD, Maria Cecilia Foncuberta, MD, Juliana Martinez Rolon, MD, Gustavo Kusminsky, MD

Blood (2017) 130 (Supplement 1): 2054.

https://doi.org/10.1182/blood.V130.Suppl_1.2054.2054

Published: 2017

Journal Articles

Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results

Neil P. Shah, MD PhD, Philippe Rousselot, MD PhD, Charles A. Schiffer, MD, Delphine Rea, MD PhD, Jorge E. Cortes, MD, Jorge Milone, MD, Hesham Mohamed, MD, Diane Healey, MS, Hagop Kantarjian, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD

Blood (2014) 124 (21): 520.

https://doi.org/10.1182/blood.V124.21.520.520

Published: 2014

Journal Articles

Long-Term Experience with Allogeneic Bone Marrow Transplant (BMT) in Chronic Myeloid Leukemia

Alicia Inés Enrico, MD, Ana Basquiera, MD, Juan Jose Napal, MD, Ana Gabriela Sturich, MD, Maria Virginia Prates, MD, Juan Garcia, MD, Sebastian Yantorno, MD, Santiago Milone, Alicia Navickas, MD, Jorge Milone, MD

Blood (2011) 118 (21): 4582.

https://doi.org/10.1182/blood.V118.21.4582.4582

Published: 2011

Journal Articles

Imatinib (IM) Treatment In Chronic Myeloid Leukemia (CML). Clinical Practice Limitations

Alicia Inés Enrico, MD, Georgina Bendek, MD, Maria Virginia Prates, MD, Virginia Guerrero, MD, Juan Jose Napal, MD, Carlos Riscala, MD, Ileana Lopez, MD, Santiago Milone, Jorge Milone, MD

Blood (2011) 118 (21): 4454.

https://doi.org/10.1182/blood.V118.21.4454.4454

Published: 2011

Journal Articles

Secondary Myelodysplastic Syndrome.(sMDS) Presentation and Evolution.

Laura Kornblihtt, Alicia Enrico, Jorge Milone, Maria Virginia Prates, Carolina B Belli, Jorge Arbelbide, Diana Lafalce, MD, Diana Penchasky, MD, Dorotea Fantl, MD, Maria Marta Rivas, MS, PhD, Maria Cabrejo, Maria Caicedo

Blood (2009) 114 (22): 4850.

https://doi.org/10.1182/blood.V114.22.4850.4850

Published: 2009

Journal Articles

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Neil P. Shah, MD, PhD, Dong-Wook Kim, MD, PhD, Hagop M. Kantarjian, MD, Philippe Rousselot, MD, PhD, Pedro Dorlhiac-Llacer, Jorge Milone, MD, Martin C Müller, MD, Yousif Matloub, Alexandre Lambert, Andreas Hochhaus, MD

Blood (2008) 112 (11): 3225.

https://doi.org/10.1182/blood.V112.11.3225.3225

Published: 2008

Journal Articles

Monitoring Minimal Residual Disease by Quantitative PCR in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission

Blood (2008) 112 (11): 4272.

https://doi.org/10.1182/blood.V112.11.4272.4272

Published: 2008

Journal Articles

90 y-Ibritumomab Tiuxetan Treatment for Relapsed and/or Refractory B-Cell Non- Hodgkin’S Lymphoma. Multi-Institutional Argentinian Study. An Update

Blood (2008) 112 (11): 5009.

https://doi.org/10.1182/blood.V112.11.5009.5009

Published: 2008

Journal Articles

90 Y-Ibritumomab Treatment for Relapsed and/or Refractory B Cell Type Non-Hodgkin’s Lymphoma. Multiinstitutional Argentinian Study.

Blood (2007) 110 (11): 4484.

https://doi.org/10.1182/blood.V110.11.4484.4484

Published: 2007

Journal Articles

Rapid Infusion of Rituximab (RIR) Is Well Tolerated and Can Safely Be Delivered in Patients with Lymphoproliferative Diseases.

Jorge Milone, MD, Virginia Prates, MD, Zoppegno Lucia, MD, Basquiera Ana, MD, Yantorno Sebastian, MD, Gelemur Marta, MD, Garcia Juan, MD

Blood (2007) 110 (11): 4503.

https://doi.org/10.1182/blood.V110.11.4503.4503

Published: 2007

Journal Articles

Clinical Outcomes in Patients with Relapsed/Refractory Acute Leukemia Treated with FLAG-IDA Regimen.

Ana L. Basquiera, MD, M. Virginia Prates, MD, Ana Gabriela Sturich, MD, Adriana R. Berretta, MD, Jorge Milone, MD, Juan Garcia, MD

Blood (2006) 108 (11): 4561.

https://doi.org/10.1182/blood.V108.11.4561.4561

Published: 2006

Journal Articles

A Phase 2 Study of 90 Y-Ibritumomab Tiuxetan ( 90 Y-Zevalin®) in Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preliminary Report of the Argentinean Cooperative Group.

Roberto E. Cacchione, MD, Jorge Milone, Javier Bordone, Juan Dupont, Gustavo Milone, Dardo Riveros, Pedro Negri, María Ardaiz, Leandro Riera, Maria Cecilia Foncuberta, Fernando Bezares

Blood (2006) 108 (11): 4688.

https://doi.org/10.1182/blood.V108.11.4688.4688

Published: 2006

Journal Articles

Fludarabine, Mitoxantrone and Dexamethasone for the First Line Treatment of Patients with Indolent Non-Hodgkin Lymphoma (NHL): GATLA First Interim Report (Grupo Argentino de Tratamiento de la Leucemia Aguda) .

Gustavo Milone, MD, A. Rodriguez, MD, Jorge Milone, MD, R.F. Bezares, MD, S. Rudoy, MD, Luis Palmer, MD, I. Cerruti, MD, Francisco Lastiri, SciD

Blood (2006) 108 (11): 4680.

https://doi.org/10.1182/blood.V108.11.4680.4680

Published: 2006

Journal Articles

Monitoring Response to Imatinib by Fluorescence In Situ Hybridization (FISH) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) in Chronic Myeloid Leukemia (CML) Patients in Chronic Phase. Experience of Argentina and Uruguay.

Blood (2006) 108 (11): 4766.

https://doi.org/10.1182/blood.V108.11.4766.4766

Published: 2006

Journal Articles

Acquired Mutations in the BCR-ABL Kinase Domain in Imatinib Resistant Patients. Multicentric Experience in Argentina and Uruguay.

Blood (2006) 108 (11): 4811.

https://doi.org/10.1182/blood.V108.11.4811.4811

Published: 2006

Journal Articles

Refractory Autoimmune Cytopenias, Either Associated with Lymphoproliferative Diseases or Idiopathic in Adult Patients, Treated with Anti-CD20 Monoclonal Antibody (Rituximab).

Guy Garay, MD, Dardo Riveros, MD, Jorge Milone, MD, Jose Fernandez, MD, Patricio Duarte, MD, Roberto Cacchione, MD, Juan Dupont, MD

Blood (2004) 104 (11): 4617.

https://doi.org/10.1182/blood.V104.11.4617.4617

Published: 2004

NARROW

Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA) Treated with Pediatric Argentine BFM-like Protocol: Real-Word Data on Prognostic Factors and Treatment

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Argentina: Results Comparing Matched Related, Unrelated or Haploidentical Donors. a Grupo Argentino De Trasplante De Medula Osea (GATMO) Experience

Comparison of Outcomes after Matched Sibling, Unrelated, or Haploidentical Allogeneic Hematopoietic Cell Transplantations (HCT). a Real World Experience of Gatmo (Grupo Argentino de Trasplante de Médula Ósea)

Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results

Long-Term Experience with Allogeneic Bone Marrow Transplant (BMT) in Chronic Myeloid Leukemia

Imatinib (IM) Treatment In Chronic Myeloid Leukemia (CML). Clinical Practice Limitations

Secondary Myelodysplastic Syndrome.(sMDS) Presentation and Evolution.

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Monitoring Minimal Residual Disease by Quantitative PCR in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission

90 y-Ibritumomab Tiuxetan Treatment for Relapsed and/or Refractory B-Cell Non- Hodgkin’S Lymphoma. Multi-Institutional Argentinian Study. An Update

90 Y-Ibritumomab Treatment for Relapsed and/or Refractory B Cell Type Non-Hodgkin’s Lymphoma. Multiinstitutional Argentinian Study.

Rapid Infusion of Rituximab (RIR) Is Well Tolerated and Can Safely Be Delivered in Patients with Lymphoproliferative Diseases.

Clinical Outcomes in Patients with Relapsed/Refractory Acute Leukemia Treated with FLAG-IDA Regimen.

A Phase 2 Study of 90 Y-Ibritumomab Tiuxetan ( 90 Y-Zevalin®) in Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preliminary Report of the Argentinean Cooperative Group.

Fludarabine, Mitoxantrone and Dexamethasone for the First Line Treatment of Patients with Indolent Non-Hodgkin Lymphoma (NHL): GATLA First Interim Report (Grupo Argentino de Tratamiento de la Leucemia Aguda) .

Monitoring Response to Imatinib by Fluorescence In Situ Hybridization (FISH) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) in Chronic Myeloid Leukemia (CML) Patients in Chronic Phase. Experience of Argentina and Uruguay.

Acquired Mutations in the BCR-ABL Kinase Domain in Imatinib Resistant Patients. Multicentric Experience in Argentina and Uruguay.

Refractory Autoimmune Cytopenias, Either Associated with Lymphoproliferative Diseases or Idiopathic in Adult Patients, Treated with Anti-CD20 Monoclonal Antibody (Rituximab).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only